SOAT1 and prostate cancer: The reduction in proliferation by SAM was reported to be due to the downregulation of cyclins, upregulation of cell cycle inhibitors, and/or downregulation of Jak/Stat pathways in prostate cancer, osteosarcoma, gall bladder carcinoma, and pancreatic cancer [59,60,61,62,63,64].